Researchers Prolong Ketamine’s Antidepressant Benefits to Two Months

Researchers prolong ketamine’s antidepressant benefits to two months

Roughly 10 percent of the U.S. population is afflicted with major depressive disorder at any given time, and up to 20 percent will exhibit MDD symptoms over their lifetimes.

New ketamine study promises extended relief for depression

For the nearly 30 percent of major depressive disorder patients who are resistant to treatment, ketamine provides some amount of normalcy, but it requires frequent treatment and can have side effects. Researchers now show in proof-of-concept experiments that it may be possible to extend ketamine's antidepressant effect from about a week to up to two months.

What to know about ketamine for treatment-resistant depression

Earlier this year, the Food and Drug Administration expanded its approval of Spravato, a nasal spray derived from ketamine that was originally approved to treat treatment-resistant depression (TRD) when taken with an oral antidepressant. The expansion means patients with TRD can now use it as a standalone treatment when their condition does not improve with antidepressant medications. While ketamine is highly effective at relieving symptoms of d…

Ketamine-Assisted Psychotherapy: Updates From the 2025 APA Annual Meeting

Ketamine-assisted psychotherapy: enhancing healing through emotional support and insight-driven therapy for depression.